Month: April 2020

LOS ANGELES, April 29, 2020 (GLOBE NEWSWIRE) — Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today new data reporting 100 percent survival in critical COVID-19 patients who were treated with Capricor’s lead asset, off-the-shelf (“allogeneic”) cardiac cell therapy CAP-1002, at Cedars-Sinai Medical Center as part of six compassionate care cases.Over the course of one month, six critically ill COVID-19 patients, all suffering from acute respiratory distress syndrome (ARDS) and five of whom were on mechanical ventilatory support, were safely treated with CAP-1002. Of the six patients treated, four of them have been discharged. Following a review of the available data,...

OXFORD, United Kingdom and MARLBOROUGH, Mass., April 29, 2020 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2020 financial results before the open of the market on Tuesday, May 5, 2020.  Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call to review the Company’s financial results at 8:00 a.m. Eastern Time the same day.  The call will be concurrently webcast.To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 8473556, approximately 15 minutes prior to start time.  To access the live...

Shareholders will not attend the General Meetings in personIn light of the COVID-19 pandemic and the measures enshrined in Royal Decree no. 4 of 9 April 2020 containing various provisions on co-ownership and company and association law in the context of the fight against the COVID-19 pandemic, the Company has decided to require shareholders to exercise their rights by granting a proxy prior to the General Meetings to a Proxyholder appointed by the Company or by completing a remote voting form in line with the instructions contained in the forms provided. Shareholders may submit their questions in writing. Physical attendance at the General Meetings is prohibited.The modified notice of meeting and new forms are available on the Company’s website (https://www.fluxys.com/en/company/fluxys-belgium/financial-information). Information...

De Vergaderingen zullen plaatsvinden zonder fysieke aanwezigheid van de aandeelhoudersGelet op de Covid-19 pandemie en de maatregelen bepaald in het koninklijk besluit nr. 4 van 9 april 2020 houdende diverse bepalingen inzake mede-eigendom en het vennootschaps- en verenigingsrecht in het kader van de strijd tegen de Covid-19 pandemie heeft de Vennootschap beslist de aandeelhouders te verplichten hun rechten uit te oefenen door vóór de Vergaderingen een volmacht te geven aan een door de Vennootschap aangestelde Volmachthouder of door een formulier voor stemming op afstand in te vullen, conform de instructies in de ter beschikking gestelde formulieren. De aandeelhouders zullen hun vragen schriftelijk kunnen stellen. De fysieke deelneming aan de Vergaderingen is niet toegelaten.De aangepaste bijeenroepingen en de nieuwe formulieren zijn...

Les Assemblées se dérouleront sans participation physique des actionnairesCompte tenu de la pandémie de Covid-19 et des mesures prévues par l’Arrêté royal n° 4 du 9 avril 2020 portant des dispositions diverses en matière de copropriété et de droit des sociétés et des associations dans le cadre de la lutte contre la pandémie Covid-19, la Société a décidé d’imposer aux actionnaires d’exercer leurs droits en accordant une procuration avant les Assemblées à un Mandataire désigné par la Société ou en remplissant un formulaire de vote à distance, conformément aux instructions reprises dans les formulaires mis à disposition. Les actionnaires pourront poser leurs questions par écrit. La participation physique aux Assemblées n’est pas admise.Les convocations adaptées ainsi que les nouveaux formulaires sont disponibles sur le site internet de la...

Preclinical Data Demonstrate Potential of Prevail’s AAV Gene Therapy Approach to Slow or Halt Progression in Multiple Neurodegenerative DiseasesCompany Provides Design Overview for Planned Phase 1/2 PR001 PROVIDE and PR006 PROCLAIM Clinical TrialsNEW YORK, April 29, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced two upcoming oral presentations and two poster presentations at the virtual 2020 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. These data underscore the robust preclinical evidence in support of Prevail’s AAV-based gene therapy approach, and highlight the company’s strategy to validate these data in multiple ongoing or planned clinical...

NASHVILLE, Tenn., April 29, 2020 (GLOBE NEWSWIRE) — SmileDirectClub today announced it has filed a complaint for patent infringement against Candid Care Co. for the operation of its Candid Studios, a copycat model of SmileDirectClub’s own SmileShop model. SmileDirectClub was issued a patent for its SmileShop and related workflow intellectual property from the United States Patent & Trademark Office (“USPTO”). The patent, U.S. Patent No. 10,636,522, further strengthens the telehealth dentistry pioneer’s efforts to bring affordable, accessible oral care to more people through its unique and innovative teledentistry platform and direct-to-consumer business model. The patent ensures no clear aligner competitor will be able to duplicate SmileDirectClub’s unique model for the next 18 years.In the complaint, SmileDirectClub details...

Equity of INVL Technology and the Company’s net asset value as of 31 March 2020 was EUR 28.84 million or EUR 2,37 per share. At the end of 2019, these figures were EUR 28.96 million and EUR 2.38 respectively.Investments of the Company into managed companies amounted to EUR 25.91 million at the end of March 2020. and EUR 25.91 million at the end of 2019.The net loss of the Company for 3 months of 2020 was EUR 119 thousand; the net loss of the Company for 3 months of 2019 amounted to EUR 331 thousand. Additional information:INVL Technology, a company that invests in IT businesses, had equity of EUR 28.8 million at the end of the first quarter of this year, or EUR 2.37 per share. The latter figure decreased by 0.4% from the end of 2019. The value of the company’s financial assets at the end of the reporting period was EUR 25.9 million...

 SUTPKIB „INVL Technology“ nuosavas kapitalas ir grynųjų aktyvų vertė 2020 m. kovo 31 d. yra 28,84 mln. EUR arba 2,37 EUR akcijai. 2019 m. pabaigoje  šie rodikliai atitinkamai buvo 28,96 mln. EUR ir 2,38 EUR.Bendrovės investicijos į valdomas įmones 2020 m. kovo mėn. pabaigoje sudarė 25,91 mln eurų, 2019 m. pabaigoje – 25,91 mln. eurų.Grynasis Bendrovės nuostolis už 2020 metų 3 mėn. buvo 119 tūkst. EUR; 2019 m. 3 mėnesių grynasis nuostolis siekė 331 tūkst. EUR.Papildoma informacija:Investicijų į informacinių technologijų verslus bendrovės „INVL Technology“ nuosavas kapitalas šių metų pirmojo ketvirčio pabaigoje buvo 28,8 mln. eurų arba 2,37 euro akcijai. Pastarasis rodiklis nuo 2019 m. pabaigos sumažėjo 0,4 proc. Bendrovės finansinio turto vertė ataskaitinio laikotarpio pabaigoje buvo 25,9 mln. eurų ir nuo metų pradžios nepasikeitė. „INVL...

TYSONS, Va., April 29, 2020 (GLOBE NEWSWIRE) — Appian (NASDAQ: APPN) today announced the United States Marine Corps (USMC) has included Appian’s low-code automation platform on its list of approved Platform as a Service (PaaS) tools for application development within the organization. According to the USMC, standardizing the PaaS offerings authorized and used within the Marine Corps is “key to ensuring operational effectiveness, cybersecurity, and investment management of Marine Corps resources.” Appian has been working with Department of Defense (DoD) customers for almost two decades, offers impact level 4 (IL4) compliance, FedRAMP certification as well as a number of additional security requirements for the DoD.Receiving this authorization affirms both the value of the Appian platform and the relationship between Appian and the...